Metabolic network as a progression biomarker of premanifest Huntington’s disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The evaluation of effective disease-modifying therapies for neurodegenerative disorders relies on objective and accurate measures of progression in at-risk individuals. Here we used a computational approach to identify a functional brain network associated with the progression of preclinical Huntington's disease (HD). METHODS: Twelve premanifest HD mutation carriers were scanned with [18F]-fluorodeoxyglucose PET to measure cerebral metabolic activity at baseline and again at 1.5, 4, and 7 years. At each time point, the subjects were also scanned with [11C]-raclopride PET and structural MRI to measure concurrent declines in caudate/putamen D2 neuroreceptor binding and tissue volume. The rate of metabolic network progression in this cohort was compared with the corresponding estimate obtained in a separate group of 21 premanifest HD carriers who were scanned twice over a 2-year period. RESULTS: In the original premanifest cohort, network analysis disclosed a significant spatial covariance pattern characterized by progressive changes in striato-thalamic and cortical metabolic activity. In these subjects, network activity increased linearly over 7 years and was not influenced by intercurrent phenoconversion. The rate of network progression was nearly identical when measured in the validation sample. Network activity progressed at approximately twice the rate of single region measurements from the same subjects. CONCLUSION: Metabolic network measurements provide a sensitive means of quantitatively evaluating disease progression in premanifest individuals. This approach may be incorporated into clinical trials to assess disease-modifying agents. TRIAL REGISTRATION: Registration is not required for observational studies. FUNDING: NIH (National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering) and CHDI Foundation Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space
Collins, D. L., Neelin, P., Peters, T. M., & Evans, A. C. (1994) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199403000-00005 · Cited by 3,431 · cited 1×
“AMontreal Neurological Institute (MNI) standard space (35).”
Neurodegenerative Diseases Target Large-Scale Human Brain Networks
Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L., & Greicius, M. D. (2009) · Neuron · doi:10.1016/j.neuron.2009.03.024 · Cited by 2,350
Tabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., Kennard, C., Hicks, S. L., Fox, N. C., Scahill, R. I., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70170-x · Cited by 984 · cited 1×
“It is noteworthy that the findings do not change when a different descriptor of disease burden (21) is used as the predictor variable in the growth models.”
A network diffusion model of disease progression in dementia
Raj, A., Kuceyeski, A., & Weiner, M. (2012) · Neuron · doi:10.1016/j.neuron.2011.12.040 · Cited by 723
Multivariate data analysis for neuroimaging data: overview and application to Alzheimer’s disease
Initiative, T. A. D. N., Habeck, C., & Stern, Y. (2010) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-010-9093-0 · Cited by 127
Self-citation
Cited by
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Huntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Self-citationGlutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration
Andersen, J. V., Markussen, K. H., Jakobsen, E., Schousboe, A., Waagepetersen, H. S., Rosenberg, P. A., & Aldana, B. I. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108719 · Cited by 371
Huntington’s disease alters human neurodevelopment
Barnat, M., Capizzi, M., Aparicio, E., Boluda, S., Wennagel, D., Kacher, R., Kassem, R., Lenoir, S., Agasse, F., Braz, B. Y., et al. (2020) · Science · doi:10.1126/science.aax3338 · Cited by 326
Brakedal, B., Dölle, C., Riemer, F., Ma, Y., Nido, G. S., Skeie, G. O., Craven, A. R., Schwarzlmüller, T., Brekke, N., Diab, J., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.001 · Cited by 323
Self-citationEANM procedure guidelines for brain PET imaging using [18F]FDG, version 3
Guedj, E., Varrone, A., Boellaard, R., Albert, N. L., Barthel, H., van Berckel, B., Brendel, M., Cecchin, D., Ekmekcioglu, O., Garibotto, V., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05603-w · Cited by 300
Metabolic resting-state brain networks in health and disease
Spetsieris, P. G., Ko, J. H., Tang, C. C., Nazem, A., Sako, W., Peng, S., Ma, Y., Dhawan, V., & Eidelberg, D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411011112 · Cited by 100
“In addition to loss of normal DMN activity, the earliest stages of neurodegenerative illnesses are often associated with increasing expression of independent, abnormal disease-related metabolic networks (15, 18, 20, 21).”
BackgroundSelf-citationFeigin, A., Evans, E. E., Fisher, T. L., Leonard, J. E., Smith, E. S., Reader, A., Mishra, V., Manber, R., Walters, K. A., Kowarski, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01919-8 · Cited by 67
Self-citationMcClory, H., Williams, D., Sapp, E., Gatune, L. W., Wang, P., DiFiglia, M., & Li, X. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0178-7 · Cited by 60
“Decreased activity of brain glucose metabolism correlates with the progression of HD [9].”
Background
Metadata
- Authors
- Tang, C. C., Feigin, A., Ma, Y., Habeck, C., Paulsen, J. S., Leenders, K. L., Teune, L. K., van Oostrom, J. C. H., Guttman, M., Dhawan, V., & Eidelberg, D.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-08-29
- Volume
- 123
- Issue
- 9
- Pages
- 4076-4088
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2081840097
- Cited by
- 120
- References
- 5
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.